Drug intelligence / Profile preview

DGC610

Development stage: Preclinical
Lead developer: Deargen

Overview

DGC610 is a preclinical rare-disease drug discovery program being co-developed by Deargen and JW Pharma. Publicly available pipeline information identifies it only by the code name DGC610 and associates it with rare disease, but does not disclose a molecular target, modality, mechanism of action, dosage form, route of administration, or specific indication. Based on current disclosed information, it should be treated as an undisclosed early-stage pharmaceutical candidate rather than a characterized clinical asset.

Other names: DGC610-Deargen-Rare DiseaseDGC-610-Deargen-Rare DiseaseDGC 610-Deargen-Rare Disease

Beyond the preview

Go deeper on DGC610.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGC610.

Explore the full profile